CHINA PHARMA HOLDINGS, INC.
CPHI evidence brief
What we can confirm
- Market Cap:
- $32.7M
What it means
What to watch
Prepared research question
What matters most for CPHI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CPHI
China Pharma Holdings, Inc. (CPHI) is a Nevada holding company with minimal revenue and cash, operating through a Chinese subsidiary and advancing a pipeline of partnered clinical-stage assets in oncology, immunology, and metabolic disease.
Key risk: Low cash runway
Market Cap
$32.7M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 49 clinical trials for CHINA PHARMA HOLDINGS, INC..
China Pharma Holdings, Inc. (CPHI) is a Nevada holding company with minimal revenue and cash, operating through a Chinese subsidiary and advancing a pipeline of partnered clinical-stage assets in oncology, immunology, and metabolic disease.
- China Pharma Holding Inc. is a Nevada holding company, not a Chinese operating company [sec_mda · as of 2026-08-14].
- Latest reported financials (as of 2026-06-30): cash & equivalents $0.3M, total revenue $0.9M, net income -$1.5M, shareholders' equity $36.2M [sec].
- The company's pipeline includes multiple Phase 2/3 trials for assets such as LP-003 (asthma, CSU), APG-2575 (CLL/SLL, AML), and ASC30 (obesity, T2DM) [catalyst].
- A corporate news release from September 2026 highlights Azurity Pharmaceuticals' growth and commercial momentum ahead of CPHI Milan 2026 [news · published 2026-09-29].
- The company disclaims any obligation to update forward-looking statements and cautions investors against undue reliance on them [sec_mda · as of 2026-08-14].
What works
- The company has a shareholders' equity of $36.2M as of 2026-06-30, providing a structural capital base [sec].
- Multiple clinical-stage programs are active, including a Phase 3 registrational study for APG-2575 in CLL/SLL (GLORA Study) and a Phase 3 study for ASC30 in obesity/T2DM (AURORA-2) [catalyst].
- A corporate news release from September 2026 indicates commercial momentum and international expansion for Azurity Pharmaceuticals, the operating entity [news · published 2026-09-29].
What to weigh
- Cash & equivalents are only $0.3M as of 2026-06-30, which is very low relative to the cost of running multiple Phase 2/3 trials [sec].
- Net income was -$1.5M as of 2026-06-30, indicating ongoing operating losses [sec].
- Total revenue is only $0.9M as of 2026-06-30, suggesting minimal product sales or licensing income [sec].
- The company is a Nevada holding company with operations conducted through a subsidiary, adding structural complexity and potential governance risks [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
Corporate structure as a Nevada holding company
“China Pharma Holding Inc. ("China Pharma") is not a Chinese operating company but a Nevada holding company. All of our operations are”
SEC MD&A · August 14, 2026
Phase 3 registrational study for APG-2575 in CLL/SLL
“Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (GLORA Study) [ 2024-01-26]”
Catalysts · January 26, 2024
Corporate growth and commercial momentum highlighted in September 2026 news
“Azurity Pharmaceuticals showcases growth and commercial momentum ahead of CPHI Milan 2026”
News · September 29, 2026
Risks & what to watch (4)›
Key risks
- Low cash runway — Cash & equivalents of only $0.3M as of 2026-06-30 may be insufficient to fund ongoing clinical trials [sec].
- Minimal revenue — Total revenue of $0.9M as of 2026-06-30 indicates very limited commercial income [sec].
- Operating losses — Net income of -$1.5M as of 2026-06-30 shows the company is not yet profitable [sec].
- Holding company structure — Being a Nevada holding company with operations through a subsidiary adds governance complexity [sec_mda · as of 2026-08-14].
What to watch
- Progress of the Phase 3 registrational study for APG-2575 (Lisaftoclax) in CLL/SLL (GLORA Study) [catalyst].
- Outcome of the Phase 3 AURORA-2 study for ASC30 in obesity/T2DM [catalyst].
- Any updates on cash position or financing given the low $0.3M cash balance as of 2026-06-30 [sec].
- Commercial developments for Azurity Pharmaceuticals as highlighted in the September 2026 news release [news · published 2026-09-29].
Sources: Catalysts · Competitor trials · News · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run CHINA PHARMA HOLDINGS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CHINA PHARMA HOLDINGS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
6
Total value held
$16K
| Holder | Shares | Value |
|---|---|---|
| citadel advisors llc | 12,924 | $8K |
| renaissance technologies llc | 11,418 | $7K |
| citigroup inc | 996 | $608 |
| ubs group ag | 389 | $237 |
| efg international ag | 40 | $24 |
| danske bank a/s | 1 | $1 |
Short Interest
as of May 20, 2026- % of float
- 0.0%
- Days to cover
- 0.3
- Shares short
- 6,992
- Daily short volume (Jul 8, 2026)
- 4.9%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CPHI short interestGovernance
Frequently asked questions
What is the AI investment thesis for CHINA PHARMA HOLDINGS, INC.?
China Pharma Holdings, Inc. (CPHI) is a Nevada holding company with minimal revenue and cash, operating through a Chinese subsidiary and advancing a pipeline of partnered clinical-stage assets in oncology, immunology, and metabolic disease.
Who is the CEO of CHINA PHARMA HOLDINGS, INC.?
Ms. Zhilin Li is the chief executive officer of CHINA PHARMA HOLDINGS, INC. (CPHI).
Where is CHINA PHARMA HOLDINGS, INC. headquartered?
CHINA PHARMA HOLDINGS, INC. (CPHI) is headquartered in Haikou, China.
What therapeutic areas does CHINA PHARMA HOLDINGS, INC. focus on?
CHINA PHARMA HOLDINGS, INC. develops therapies across Oncology, Immunology, Metabolic, Respiratory, Dermatology, Hematology, Nephrology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.